Your browser doesn't support javascript.
loading
Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment.
Arantes, Lidia Maria Rebolho Batista; Silva-Oliveira, Renato José; de Carvalho, Ana Carolina; Melendez, Matias Eliseo; Sorroche, Bruna Pereira; de Jesus Teixeira, Renan; Tostes, Katiane; Palmero, Edenir Inez; Reis, Rui Manuel; Carvalho, André Lopes.
Afiliação
  • Arantes LMRB; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
  • Silva-Oliveira RJ; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
  • de Carvalho AC; Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos, Brazil.
  • Melendez ME; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
  • Sorroche BP; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
  • de Jesus Teixeira R; Molecular Carcinogenesis Program, National Cancer Institute - INCA, Rio de Janeiro, Brazil.
  • Tostes K; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
  • Palmero EI; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
  • Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
  • Carvalho AL; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
Head Neck ; 46(3): 461-472, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38095042
BACKGROUND: Epidermal growth factor receptor (EGFR) is frequently activated in head and neck squamous cell carcinoma (HNSCC) and serves as a valuable target for therapy. Despite the availability of the EGFR inhibitors Cetuximab, Afatinib, and Allitinib, there are limited predictive markers for their response. Understanding molecular aberrations in HNSCC could facilitate the identification of new strategies for patient clinical and biological classification, offering novel therapeutic avenues. METHODS: We assessed CCNA1, DCC, MGMT, CDKN2A/p16, and DAPK methylation status in HNSCC cell lines and their association with anti-EGFR treatment response. RESULTS: MGMT methylation status displayed high sensitivity and specificity in distinguishing sensitive and resistant HNSCC cell lines to Afatinib (AUC = 0.955) and Allitinib (AUC = 0.935). Moreover, DAPK methylation status predicted response to Allitinib with high accuracy (AUC = 0.852), indicating their putative predictive biomarker roles. CONCLUSION: These findings hold promise for the development of more personalized and effective treatment approaches for HNSCC patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Acrilamidas / Carcinoma de Células Escamosas / Neoplasias de Cabeça e Pescoço Limite: Humans Idioma: En Revista: Head Neck Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Acrilamidas / Carcinoma de Células Escamosas / Neoplasias de Cabeça e Pescoço Limite: Humans Idioma: En Revista: Head Neck Ano de publicação: 2024 Tipo de documento: Article